Broedl UC - Search Results

1

Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.

Perkins BA, Cherney DZ, Partridge H, Soleymanlou N, Tschirhart H, Zinman B, Fagan NM, Kaspers S, Woerle HJ, Broedl UC, Johansen OE. Perkins BA, et al. Among authors: broedl uc. Diabetes Care. 2014 May;37(5):1480-3. doi: 10.2337/dc13-2338. Epub 2014 Mar 4. Diabetes Care. 2014. PMID: 24595630 Clinical Trial.

2

Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes.

Perkins BA, Cherney DZ, Soleymanlou N, Lee JA, Partridge H, Tschirhart H, Zinman B, Mazze R, Fagan N, Kaspers S, Woerle HJ, Broedl UC, Johansen OE. Perkins BA, et al. Among authors: broedl uc. PLoS One. 2015 Nov 6;10(11):e0141085. doi: 10.1371/journal.pone.0141085. eCollection 2015. PLoS One. 2015. PMID: 26544192 Free PMC article.

3

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.

Macha S, Mattheus M, Halabi A, Pinnetti S, Woerle HJ, Broedl UC. Macha S, et al. Among authors: broedl uc. Diabetes Obes Metab. 2014 Mar;16(3):215-22. doi: 10.1111/dom.12182. Epub 2013 Aug 19. Diabetes Obes Metab. 2014. PMID: 23859488 Clinical Trial.

4

Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.

Macha S, Rose P, Mattheus M, Cinca R, Pinnetti S, Broedl UC, Woerle HJ. Macha S, et al. Among authors: broedl uc. Diabetes Obes Metab. 2014 Feb;16(2):118-23. doi: 10.1111/dom.12183. Epub 2013 Aug 19. Diabetes Obes Metab. 2014. PMID: 23859534 Clinical Trial.

5

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.

Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC; EMPA-REG PIO™ trial investigators. Kovacs CS, et al. Among authors: broedl uc. Diabetes Obes Metab. 2014 Feb;16(2):147-58. doi: 10.1111/dom.12188. Epub 2013 Aug 22. Diabetes Obes Metab. 2014. PMID: 23906415 Clinical Trial.

6

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.

Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ; EMPA-REG BASALTM trial investigators. Rosenstock J, et al. Among authors: broedl uc. Diabetes Obes Metab. 2015 Oct;17(10):936-48. doi: 10.1111/dom.12503. Epub 2015 Jul 14. Diabetes Obes Metab. 2015. PMID: 26040302 Free PMC article. Clinical Trial.

7

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).

Pieber TR, Famulla S, Eilbracht J, Cescutti J, Soleymanlou N, Johansen OE, Woerle HJ, Broedl UC, Kaspers S. Pieber TR, et al. Among authors: broedl uc. Diabetes Obes Metab. 2015 Oct;17(10):928-35. doi: 10.1111/dom.12494. Epub 2015 Jun 24. Diabetes Obes Metab. 2015. PMID: 26080652 Free PMC article. Clinical Trial.

8

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.

Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OE. Chilton R, et al. Among authors: broedl uc. Diabetes Obes Metab. 2015 Dec;17(12):1180-93. doi: 10.1111/dom.12572. Epub 2015 Oct 9. Diabetes Obes Metab. 2015. PMID: 26343814 Free PMC article. Clinical Trial.

9

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.

Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M. Cherney DZ, et al. Among authors: broedl uc. Circulation. 2014 Feb 4;129(5):587-97. doi: 10.1161/CIRCULATIONAHA.113.005081. Epub 2013 Dec 13. Circulation. 2014. PMID: 24334175 Clinical Trial.

10

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.

Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle HJ. Ferrannini E, et al. Among authors: broedl uc. J Clin Invest. 2014 Feb;124(2):499-508. doi: 10.1172/JCI72227. Epub 2014 Jan 27. J Clin Invest. 2014. PMID: 24463454 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

112 results

Search Page